Caribou Biosciences (CRBU) Asset Writedowns and Impairment (2025)
Caribou Biosciences' (CRBU) quarterly Asset Writedowns and Impairment came in at $2.2 million in Q2 2025, down 76.09% on a QoQ basis from $9.2 million in Q1 2025.
Caribou Biosciences (CRBU) Asset Writedowns and Impairment (2025) Analysis & Trends
Caribou Biosciences (CRBU) has 1 years of Asset Writedowns and Impairment data on file, last reported at $2.2 million in Q2 2025.
- On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $2.2 million in Q2 2025; TTM through Dec 2025 was $2.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $12.1 million, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q2 2025 stood at $2.2 million, down from $9.2 million in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for CRBU reached as high as $9.2 million in Q1 2025 and fell as low as $2.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Caribou Biosciences | 152.90 Mn | 35.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 2.20 Mn |
| Jun 30, 2025 | 2.20 Mn |
| Mar 31, 2025 | 9.20 Mn |
| Mar 31, 2025 | 9.20 Mn |